Lorazepam

證據等級: L5

預測適應症: 10 個

Lorazepam: From Anxiety and Sedation to Trigeminal Nerve Neoplasm

One-Sentence Summary

Lorazepam is a benzodiazepine historically used for anxiety, sedation, and short-term insomnia management. The TxGNN model predicts it may be effective for Trigeminal Nerve Neoplasm, with no clinical trials and no publications currently supporting this direction — this prediction is most likely a knowledge graph false positive and should be treated as a warning signal rather than a genuine repurposing candidate.

Quick Overview

Item	Content
Original Indication	Anxiety and sedation (benzodiazepine class; no NL marketing authorisation on record)
Predicted New Indication	Trigeminal Nerve Neoplasm
TxGNN Prediction Score	99.87%
Evidence Level	L5
NL Market Status	Not marketed
Number of Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the provided dataset. Based on known pharmacological information, Lorazepam is a benzodiazepine — a positive allosteric modulator at the GABA-A receptor — that enhances chloride ion influx to produce sedative, anxiolytic, muscle-relaxant, and anticonvulsant effects. Its clinical history includes short-term management of anxiety disorders, procedural sedation, and seizure control.

There is no established mechanistic link between GABA-A receptor modulation and trigeminal nerve neoplasm biology. Lorazepam has no known antitumour, anti-angiogenic, or antiproliferative activity. Trigeminal nerve tumours are space-occupying lesions managed primarily through neurosurgery or radiotherapy; benzodiazepines play no recognised role in their pathophysiology or treatment.

The exceptionally high TxGNN score (0.9987, rank 403) is almost certainly attributable to knowledge graph noise or feature overfitting: the broad connectivity between drug nodes and neurological disease nodes in the underlying knowledge graph systematically inflates scores for rare neuro-oncological conditions, generating false positives. This is a recognised limitation of graph-based prediction models and should trigger a graph-quality audit rather than clinical follow-up.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Netherlands Market Information

Lorazepam currently holds no CBG-MEB marketing authorisations in the Netherlands and is not registered for any indication in the Dutch market. There are therefore no RVG numbers, SmPC documents, or approved indication texts available from the national register.

For reference: in other jurisdictions where Lorazepam is authorised, the SmPC and PIL should be consulted for safety information, approved indications, and prescribing conditions.

Safety Considerations

Please refer to the SmPC (Summary of Product Characteristics) for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: This is an L5 prediction — TxGNN model output only — with no supporting clinical trials, no published literature, no mechanistic basis, and no plausible pharmacological rationale connecting Lorazepam to trigeminal nerve neoplasm. The high numeric score almost certainly reflects systematic false-positive generation in the knowledge graph rather than a genuine drug-disease signal.

To proceed, the following is needed:

Graph quality audit: Examine whether the TxGNN knowledge graph systematically over-connects benzodiazepine nodes to rare neurological disease nodes, and apply score recalibration or edge-weight correction
Mechanistic hypothesis generation: Identify, if any, a biological pathway through which GABA-A modulation could influence trigeminal nerve tumour growth or survival — currently none has been proposed
Minimum evidence threshold: At minimum one peer-reviewed case report or in vitro study documenting any benzodiazepine activity relevant to peripheral nerve neoplasm before any further investment in this candidate is warranted
MOA data gap resolution: Retrieve and integrate the full Lorazepam DrugBank entry (DrugBank ID: DB00186) to support future mechanistic plausibility assessments across all predicted indications
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.